Cargando…

Medical device assessment: scientific evidence examined by the French national agency for health – a descriptive study

BACKGROUND: Scientific evidence supports decision-making on the use of implantable medical devices (IMDs) in clinical practice, but IMDs are thought to be far less investigated than drugs. In the USA, studies have shown that approval process of high-risk medical devices was often based on insufficie...

Descripción completa

Detalles Bibliográficos
Autores principales: Huot, Laure, Decullier, Evelyne, Maes-Beny, Karen, Chapuis, Francois R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490794/
https://www.ncbi.nlm.nih.gov/pubmed/22853740
http://dx.doi.org/10.1186/1471-2458-12-585
_version_ 1782248874259251200
author Huot, Laure
Decullier, Evelyne
Maes-Beny, Karen
Chapuis, Francois R
author_facet Huot, Laure
Decullier, Evelyne
Maes-Beny, Karen
Chapuis, Francois R
author_sort Huot, Laure
collection PubMed
description BACKGROUND: Scientific evidence supports decision-making on the use of implantable medical devices (IMDs) in clinical practice, but IMDs are thought to be far less investigated than drugs. In the USA, studies have shown that approval process of high-risk medical devices was often based on insufficiently robust studies, suggesting that evidence prior to marketing may not be adequate. This study aimed to ascertain level of evidence available for IMDs access to reimbursement in France. METHODS: The objective was to examine the scientific evidence used for IMDs assessment by the French National Authority for Health. We collected all public documents summarising supportive clinical data and opinions concerning IMDs issued in 2008. An opinion qualifies the expected benefit (EB) of the IMD assessed as sufficient or insufficient, and if sufficient, the level of improvement of the expected benefit (IEB) on a scale from major (level I) to no improvement (level V). For each opinion, the study with the highest level of evidence of efficacy data, and its design were collected, or, where no studies were available, any other data sources used to establish the opinion. RESULTS: One hundred and two opinions were analysed, with 72 reporting at least one study used for assessment (70.6%). When considering the study with the highest level of evidence: 34 were clinical non-comparative studies (47.2%); 29 were clinical comparative studies of which 25 randomised controlled trials (40.3%); 5 were meta-analyses of randomised controlled trials (6.9%); and 4 were systematic literature reviews (5.6%). The opinions were significantly different according to the study design (p < 0.001). The most frequent design for insufficient EB, IEB level V and IEB level IV was a non-comparative study (10/19, 52.6%; 15/24, 62.5%; and 8/15, 53.3%; respectively). For the 30 opinions with no supporting clinical study, 16 (53.3%) were based on an expert-based process, 9 (30.0%) were based on the conclusions of a previous opinion (all concluding IEB level V), and 5 (16.7%) reported no data (concluding insufficient EB for 4 and IEB level V for 1). CONCLUSIONS: This study confirmed that level of evidence of clinical evaluation of IMDs is low and needs to be improved.
format Online
Article
Text
id pubmed-3490794
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34907942012-11-07 Medical device assessment: scientific evidence examined by the French national agency for health – a descriptive study Huot, Laure Decullier, Evelyne Maes-Beny, Karen Chapuis, Francois R BMC Public Health Research Article BACKGROUND: Scientific evidence supports decision-making on the use of implantable medical devices (IMDs) in clinical practice, but IMDs are thought to be far less investigated than drugs. In the USA, studies have shown that approval process of high-risk medical devices was often based on insufficiently robust studies, suggesting that evidence prior to marketing may not be adequate. This study aimed to ascertain level of evidence available for IMDs access to reimbursement in France. METHODS: The objective was to examine the scientific evidence used for IMDs assessment by the French National Authority for Health. We collected all public documents summarising supportive clinical data and opinions concerning IMDs issued in 2008. An opinion qualifies the expected benefit (EB) of the IMD assessed as sufficient or insufficient, and if sufficient, the level of improvement of the expected benefit (IEB) on a scale from major (level I) to no improvement (level V). For each opinion, the study with the highest level of evidence of efficacy data, and its design were collected, or, where no studies were available, any other data sources used to establish the opinion. RESULTS: One hundred and two opinions were analysed, with 72 reporting at least one study used for assessment (70.6%). When considering the study with the highest level of evidence: 34 were clinical non-comparative studies (47.2%); 29 were clinical comparative studies of which 25 randomised controlled trials (40.3%); 5 were meta-analyses of randomised controlled trials (6.9%); and 4 were systematic literature reviews (5.6%). The opinions were significantly different according to the study design (p < 0.001). The most frequent design for insufficient EB, IEB level V and IEB level IV was a non-comparative study (10/19, 52.6%; 15/24, 62.5%; and 8/15, 53.3%; respectively). For the 30 opinions with no supporting clinical study, 16 (53.3%) were based on an expert-based process, 9 (30.0%) were based on the conclusions of a previous opinion (all concluding IEB level V), and 5 (16.7%) reported no data (concluding insufficient EB for 4 and IEB level V for 1). CONCLUSIONS: This study confirmed that level of evidence of clinical evaluation of IMDs is low and needs to be improved. BioMed Central 2012-08-01 /pmc/articles/PMC3490794/ /pubmed/22853740 http://dx.doi.org/10.1186/1471-2458-12-585 Text en Copyright ©2012 Huot et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Huot, Laure
Decullier, Evelyne
Maes-Beny, Karen
Chapuis, Francois R
Medical device assessment: scientific evidence examined by the French national agency for health – a descriptive study
title Medical device assessment: scientific evidence examined by the French national agency for health – a descriptive study
title_full Medical device assessment: scientific evidence examined by the French national agency for health – a descriptive study
title_fullStr Medical device assessment: scientific evidence examined by the French national agency for health – a descriptive study
title_full_unstemmed Medical device assessment: scientific evidence examined by the French national agency for health – a descriptive study
title_short Medical device assessment: scientific evidence examined by the French national agency for health – a descriptive study
title_sort medical device assessment: scientific evidence examined by the french national agency for health – a descriptive study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3490794/
https://www.ncbi.nlm.nih.gov/pubmed/22853740
http://dx.doi.org/10.1186/1471-2458-12-585
work_keys_str_mv AT huotlaure medicaldeviceassessmentscientificevidenceexaminedbythefrenchnationalagencyforhealthadescriptivestudy
AT decullierevelyne medicaldeviceassessmentscientificevidenceexaminedbythefrenchnationalagencyforhealthadescriptivestudy
AT maesbenykaren medicaldeviceassessmentscientificevidenceexaminedbythefrenchnationalagencyforhealthadescriptivestudy
AT chapuisfrancoisr medicaldeviceassessmentscientificevidenceexaminedbythefrenchnationalagencyforhealthadescriptivestudy